Compare Eli Lilly And Co (LLY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Total World Stock Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Vanguard Total World Stock Index Fund ETF trades at $159.95 (market cap $101.70B). The key difference: Eli Lilly And Co is far larger — about 10.2× Vanguard Total World Stock Index Fund ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| LLY | VT | |
|---|---|---|
Market Cap | $1.04T | $101.70B |
Volume | 3,064,878 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $162.39 |
52-Week Low | $799.57 | $134.19 |
Typical Hold Time | 93 Days | 53 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Vanguard Total World Stock ETF (VT) trades at $159.84, up 0.13% with a bearish technical signal from moving averages. The ETF provides exposure to over 9,700 global stocks with a 0.06% expense ratio, though key financial ratios remain unavailable. Recent news highlights VT's diversification benefits and competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF.
VT offers broad global diversification but faces headwinds from technical bearish signals and expense ratio competition. The outlook remains neutral with institutional interest mixed; risks include market volatility and geopolitical factors. Long-term investors may value its comprehensive market coverage despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
